Point-of-care diagnosis is a test performed on the site of patient care that provides immediate results.Infectious diseases are caused by various microorganisms, such as viruses, bacteria, fungi and parasites.Instant diagnosis of infectious diseases can improve disease management and detection, reducing the time between disease testing and diagnosis of infection.It also reduces postoperative care time, improves outcomes, improves accuracy of outcomes, and provides a simple way to diagnose infectious diseases, broadly reducing the risk of HIV, tuberculosis, influenza, tropical diseases, and sexually transmitted infections.
麻豆原创 Analysis and Insights: Global Infectious Disease Point of Care Diagnostics 麻豆原创
The global Infectious Disease Point of Care Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Infectious Disease Point of Care Diagnostics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Infectious Disease Point of Care Diagnostics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Infectious Disease Point of Care Diagnostics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Infectious Disease Point of Care Diagnostics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Infectious Disease Point of Care Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Infectious Disease Point of Care Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Abbott
Siemens
GE Healthcare
Accriva
Terumo
BioMerieux
Diasorin
Roche
Danaher Corporation
BD
Bio-Rad Laboratories
Cavidi
Cepheid
Diaxonhit
Eiken Chemical
EMD Millipore
Epitope Diagnostic
Euroimmun
Gold Standard Diagnostics
Hologic
Immunetics
InBios International
Segment by Type
Over-the-counter (OTC) Testing Kits
Prescription-based Testing Kits
Segment by Application
Bacterial Infections
Fungal Infection
Virus Infection
Cardiovascular Infection
Gastrointestinal Infection
Sexually Transmitted Disease (STD) Infection
Central Nervous System Infection
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Infectious Disease Point of Care Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Infectious Disease Point of Care Diagnostics companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Infectious Disease Point of Care Diagnostics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Infectious Disease Point of Care Diagnostics 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Over-the-counter (OTC) Testing Kits
1.2.3 Prescription-based Testing Kits
1.3 麻豆原创 by Application
1.3.1 Global Infectious Disease Point of Care Diagnostics 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Bacterial Infections
1.3.3 Fungal Infection
1.3.4 Virus Infection
1.3.5 Cardiovascular Infection
1.3.6 Gastrointestinal Infection
1.3.7 Sexually Transmitted Disease (STD) Infection
1.3.8 Central Nervous System Infection
1.3.9 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Infectious Disease Point of Care Diagnostics 麻豆原创 Perspective (2019-2030)
2.2 Global Infectious Disease Point of Care Diagnostics Growth Trends by Region
2.2.1 Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Infectious Disease Point of Care Diagnostics Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Infectious Disease Point of Care Diagnostics Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Infectious Disease Point of Care Diagnostics 麻豆原创 Dynamics
2.3.1 Infectious Disease Point of Care Diagnostics Industry Trends
2.3.2 Infectious Disease Point of Care Diagnostics 麻豆原创 Drivers
2.3.3 Infectious Disease Point of Care Diagnostics 麻豆原创 Challenges
2.3.4 Infectious Disease Point of Care Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Infectious Disease Point of Care Diagnostics by Players
3.1.1 Global Infectious Disease Point of Care Diagnostics Revenue by Players (2019-2024)
3.1.2 Global Infectious Disease Point of Care Diagnostics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Infectious Disease Point of Care Diagnostics, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Infectious Disease Point of Care Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global Infectious Disease Point of Care Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Infectious Disease Point of Care Diagnostics Revenue in 2023
3.5 Global Key Players of Infectious Disease Point of Care Diagnostics Head office and Area Served
3.6 Global Key Players of Infectious Disease Point of Care Diagnostics, Product and Application
3.7 Global Key Players of Infectious Disease Point of Care Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Infectious Disease Point of Care Diagnostics Breakdown Data by Type
4.1 Global Infectious Disease Point of Care Diagnostics Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Infectious Disease Point of Care Diagnostics Forecasted 麻豆原创 Size by Type (2025-2030)
5 Infectious Disease Point of Care Diagnostics Breakdown Data by Application
5.1 Global Infectious Disease Point of Care Diagnostics Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Infectious Disease Point of Care Diagnostics Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size (2019-2030)
6.2 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type
6.2.1 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Type (2019-2030)
6.3 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application
6.3.1 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Application (2019-2030)
6.4 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country
6.4.1 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size (2019-2030)
7.2 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type
7.2.1 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Type (2019-2030)
7.3 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application
7.3.1 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Application (2019-2030)
7.4 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country
7.4.1 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Infectious Disease Point of Care Diagnostics 麻豆原创 Size (2019-2030)
8.2 China Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type
8.2.1 China Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2019-2024)
8.2.2 China Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2025-2030)
8.2.3 China Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Type (2019-2030)
8.3 China Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application
8.3.1 China Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2019-2024)
8.3.2 China Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2025-2030)
8.3.3 China Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size (2019-2030)
9.2 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type
9.2.1 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Type (2019-2030)
9.3 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application
9.3.1 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Application (2019-2030)
9.4 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Region
9.4.1 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Infectious Disease Point of Care Diagnostics 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Infectious Disease Point of Care Diagnostics Introduction
11.1.4 Abbott Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.1.5 Abbott Recent Developments
11.2 Siemens
11.2.1 Siemens Company Details
11.2.2 Siemens Business Overview
11.2.3 Siemens Infectious Disease Point of Care Diagnostics Introduction
11.2.4 Siemens Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.2.5 Siemens Recent Developments
11.3 GE Healthcare
11.3.1 GE Healthcare Company Details
11.3.2 GE Healthcare Business Overview
11.3.3 GE Healthcare Infectious Disease Point of Care Diagnostics Introduction
11.3.4 GE Healthcare Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.3.5 GE Healthcare Recent Developments
11.4 Accriva
11.4.1 Accriva Company Details
11.4.2 Accriva Business Overview
11.4.3 Accriva Infectious Disease Point of Care Diagnostics Introduction
11.4.4 Accriva Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.4.5 Accriva Recent Developments
11.5 Terumo
11.5.1 Terumo Company Details
11.5.2 Terumo Business Overview
11.5.3 Terumo Infectious Disease Point of Care Diagnostics Introduction
11.5.4 Terumo Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.5.5 Terumo Recent Developments
11.6 BioMerieux
11.6.1 BioMerieux Company Details
11.6.2 BioMerieux Business Overview
11.6.3 BioMerieux Infectious Disease Point of Care Diagnostics Introduction
11.6.4 BioMerieux Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.6.5 BioMerieux Recent Developments
11.7 Diasorin
11.7.1 Diasorin Company Details
11.7.2 Diasorin Business Overview
11.7.3 Diasorin Infectious Disease Point of Care Diagnostics Introduction
11.7.4 Diasorin Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.7.5 Diasorin Recent Developments
11.8 Roche
11.8.1 Roche Company Details
11.8.2 Roche Business Overview
11.8.3 Roche Infectious Disease Point of Care Diagnostics Introduction
11.8.4 Roche Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.8.5 Roche Recent Developments
11.9 Danaher Corporation
11.9.1 Danaher Corporation Company Details
11.9.2 Danaher Corporation Business Overview
11.9.3 Danaher Corporation Infectious Disease Point of Care Diagnostics Introduction
11.9.4 Danaher Corporation Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.9.5 Danaher Corporation Recent Developments
11.10 BD
11.10.1 BD Company Details
11.10.2 BD Business Overview
11.10.3 BD Infectious Disease Point of Care Diagnostics Introduction
11.10.4 BD Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.10.5 BD Recent Developments
11.11 Bio-Rad Laboratories
11.11.1 Bio-Rad Laboratories Company Details
11.11.2 Bio-Rad Laboratories Business Overview
11.11.3 Bio-Rad Laboratories Infectious Disease Point of Care Diagnostics Introduction
11.11.4 Bio-Rad Laboratories Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.11.5 Bio-Rad Laboratories Recent Developments
11.12 Cavidi
11.12.1 Cavidi Company Details
11.12.2 Cavidi Business Overview
11.12.3 Cavidi Infectious Disease Point of Care Diagnostics Introduction
11.12.4 Cavidi Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.12.5 Cavidi Recent Developments
11.13 Cepheid
11.13.1 Cepheid Company Details
11.13.2 Cepheid Business Overview
11.13.3 Cepheid Infectious Disease Point of Care Diagnostics Introduction
11.13.4 Cepheid Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.13.5 Cepheid Recent Developments
11.14 Diaxonhit
11.14.1 Diaxonhit Company Details
11.14.2 Diaxonhit Business Overview
11.14.3 Diaxonhit Infectious Disease Point of Care Diagnostics Introduction
11.14.4 Diaxonhit Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.14.5 Diaxonhit Recent Developments
11.15 Eiken Chemical
11.15.1 Eiken Chemical Company Details
11.15.2 Eiken Chemical Business Overview
11.15.3 Eiken Chemical Infectious Disease Point of Care Diagnostics Introduction
11.15.4 Eiken Chemical Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.15.5 Eiken Chemical Recent Developments
11.16 EMD Millipore
11.16.1 EMD Millipore Company Details
11.16.2 EMD Millipore Business Overview
11.16.3 EMD Millipore Infectious Disease Point of Care Diagnostics Introduction
11.16.4 EMD Millipore Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.16.5 EMD Millipore Recent Developments
11.17 Epitope Diagnostic
11.17.1 Epitope Diagnostic Company Details
11.17.2 Epitope Diagnostic Business Overview
11.17.3 Epitope Diagnostic Infectious Disease Point of Care Diagnostics Introduction
11.17.4 Epitope Diagnostic Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.17.5 Epitope Diagnostic Recent Developments
11.18 Euroimmun
11.18.1 Euroimmun Company Details
11.18.2 Euroimmun Business Overview
11.18.3 Euroimmun Infectious Disease Point of Care Diagnostics Introduction
11.18.4 Euroimmun Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.18.5 Euroimmun Recent Developments
11.19 Gold Standard Diagnostics
11.19.1 Gold Standard Diagnostics Company Details
11.19.2 Gold Standard Diagnostics Business Overview
11.19.3 Gold Standard Diagnostics Infectious Disease Point of Care Diagnostics Introduction
11.19.4 Gold Standard Diagnostics Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.19.5 Gold Standard Diagnostics Recent Developments
11.20 Hologic
11.20.1 Hologic Company Details
11.20.2 Hologic Business Overview
11.20.3 Hologic Infectious Disease Point of Care Diagnostics Introduction
11.20.4 Hologic Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.20.5 Hologic Recent Developments
11.21 Immunetics
11.21.1 Immunetics Company Details
11.21.2 Immunetics Business Overview
11.21.3 Immunetics Infectious Disease Point of Care Diagnostics Introduction
11.21.4 Immunetics Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.21.5 Immunetics Recent Developments
11.22 InBios International
11.22.1 InBios International Company Details
11.22.2 InBios International Business Overview
11.22.3 InBios International Infectious Disease Point of Care Diagnostics Introduction
11.22.4 InBios International Revenue in Infectious Disease Point of Care Diagnostics Business (2019-2024)
11.22.5 InBios International Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbott
Siemens
GE Healthcare
Accriva
Terumo
BioMerieux
Diasorin
Roche
Danaher Corporation
BD
Bio-Rad Laboratories
Cavidi
Cepheid
Diaxonhit
Eiken Chemical
EMD Millipore
Epitope Diagnostic
Euroimmun
Gold Standard Diagnostics
Hologic
Immunetics
InBios International
听
听
*If Applicable.
